INHALON BIOPHARMA, INC.
Inhaled immunotherapy for acute respiratory infections
Morrisville, United States · Founded 2022 · $15.1M raised
- Headquarters
- Morrisville, North Carolina
- Founded
- 2022
- Business Model
- B2B
- Website
- inhalon.com
- Total Funding
- $15.1M
- Last Round
- $3.1M SeedJun 2023
- Rounds
- 3
About
Inhalon Biopharma is a clinical-stage biotechnology company developing inhaled antibody treatments for acute respiratory infections including RSV, influenza, human metapneumovirus, and SARS-CoV-2. Their proprietary muco-trapping antibody platform enables inhaled antibodies to trap pathogens in lung mucus, blocking infection and facilitating rapid elimination through natural mucus clearance. Inhalon has advanced multiple programs through Phase 1 clinical trials supported by NIH and U.S. Army Medical Research grants.
Summary
INHALON BIOPHARMA, INC. is a Biotech company based in Morrisville, United States, founded in 2022. It has raised $15.1M in total across 3 rounds, most recently a $3.1M Seed round in Jun 2023. Investors include Life Science Angels, JSR Life Sciences and U.S. Army Medical Research & Development Command.
Tech & App Stack
3 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jun 2023
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...